# Grifols S.A. (GRFS)

Source: https://www.quantisnow.com/company/GRFS
Generated: 2026-11-10T06:39:51.435Z

- Ticker: GRFS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001438569
- Website: grifols.com

## About

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

## Latest GRFS news and filings

- 2026-11-02 16:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6766673)
- 2026-11-02 16:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6766668)
- 2026-08-10 11:00 UTC [Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency](https://www.quantisnow.com/insight/grifols-announces-last-patient-last-visit-in-sparta-its-phase-6672578)
- 2026-07-30 14:48 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6655463)
- 2026-07-16 12:00 UTC [Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins](https://www.quantisnow.com/insight/grifols-doses-first-patients-in-two-phase-3-trials-to-6639039)
- 2026-06-22 18:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6610531)
- 2026-06-18 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6608444)
- 2026-06-15 12:00 UTC [Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.](https://www.quantisnow.com/insight/grifols-launches-fesilty-fibrinogen-human-chmt-in-the-us-6601851)
- 2026-05-15 17:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6556671)
- 2026-05-14 20:05 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-grifols-sa-6553767)
- 2026-05-07 18:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6538386)
- 2026-04-17 20:11 UTC [SEC Form 20-F filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-grifols-sa-6504797)
- 2026-04-14 20:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6499750)
- 2026-03-24 20:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6467396)
- 2026-03-17 12:28 UTC [Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease](https://www.quantisnow.com/insight/grifols-shares-results-from-its-chronos-platform-identifying-early-molecular-6451297)
- 2026-02-26 21:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6416581)
- 2026-02-26 19:48 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6415601)
- 2026-02-12 22:54 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-grifols-sa-6390549)
- 2026-01-08 20:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6342870)
- 2025-12-16 14:26 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6317541)
- 2025-11-12 21:03 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-grifols-sa-6274203)
- 2025-11-04 18:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6258687)
- 2025-09-29 12:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6213920)
- 2025-07-30 10:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6137458)
- 2025-07-29 17:59 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6136115)
- 2025-07-29 11:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6135338)
- 2025-06-12 00:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6082939)
- 2025-06-05 19:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6074233)
- 2025-05-30 20:05 UTC [Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting](https://www.quantisnow.com/insight/mason-capital-management-to-support-grifols-recommended-director-slate-at-6064939)
- 2025-05-12 16:36 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6032500)
- 2025-05-06 16:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6020361)
- 2025-05-02 16:51 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-6015288)
- 2025-04-09 19:30 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Grifols S.A.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-grifols-sa-5982682)
- 2025-04-02 21:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5973486)
- 2025-03-31 18:48 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5966765)
- 2025-03-10 15:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5935340)
- 2025-02-27 22:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5915427)
- 2025-02-26 22:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5912102)
- 2025-02-26 22:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5912095)
- 2025-02-25 16:53 UTC [SEC Form 6-K] [SEC Form 6-K filed by Grifols S.A.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-grifols-sa-5907599)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GRFS
- Earnings history: https://www.quantisnow.com/earnings/GRFS
- Dividend history: https://www.quantisnow.com/dividends/GRFS
- Insider transactions: https://www.quantisnow.com/insiders/GRFS
- Options chain: https://www.quantisnow.com/options/GRFS
- SEC 8-K filings only: https://www.quantisnow.com/company/GRFS/8-k
- RSS and alerts for GRFS: https://www.quantisnow.com/docs/rss-feeds.md